ExpressPoints
Next-Generation Therapeutic Strategies for Relapsed/Refractory Multiple Myeloma: Targeting BCMA

Gain key clinical insights fast, with this short slideset from CCO on key considerations for optimal use of anti-BMCA therapy for patients with relapsed/refractory multiple myeloma.

Suzanne Lentzsch, MD, PhD
Sagar Lonial, MD
Thomas G. Martin, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 2.64 MB
Released: October 5, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
GlaxoSmithKline
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Related Content

Downloadable slideset from a live webinar from Clinical Care Options (CCO) on the diagnosis and staging of light-chain amyloidosis

Shaji K. Kumar, MD Released: January 18, 2022

Downloadable slideset from a live webinar from Clinical Care Options (CCO) on the initial management of light-chain amyloidosis

Vaishali Sanchorawala, MD Released: January 18, 2022

Downloadable slideset from a live webinar from Clinical Care Options (CCO) on the management of light-chain amyloidosis at relapse

Ankit Kansagra, MD Released: January 18, 2022

Ashley Leak Bryant, PhD, RN, OCN, FAAN, shares strategies for managing lower-risk myelodysplastic syndromes in this commentary from Clinical Care Options (CCO)

Ashley Leak Bryant, PhD, RN, OCN, FAAN Released: January 14, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings